Autologous, second-generation, bispecific CD20/BCMA-directed chimeric antigen receptor T-cell (CAR-T) therapy. Patient T cells are gene-engineered to express a CAR recognizing CD20 and BCMA; engagement triggers T-cell activation, cytotoxic killing, and cytokine release, depleting CD20+ B cells and BCMA+ plasmablasts/long-lived plasma cells to reduce autoantibody-mediated pathology. Administered as a single IV infusion.